目的 探討復(fù)方杜仲膠囊聯(lián)合貝那普利治療老年高血壓的臨床療效。方法 選擇2020年1月-2022年1月在石家莊市第三醫(yī)院診療的128例老年高血壓患者,隨機數(shù)字表法將患者分為對照組和治療組,每組各64例。對照組口服鹽酸貝那普利片,10 mg/次,1次/d。在對照組的基礎(chǔ)上,治療組口服復(fù)方杜仲膠囊,5粒/次,3次/d。兩組用藥7 d。觀察兩組患者臨床療效,比較治療前后兩組患者癥狀緩解時間,收縮壓(SBP)和舒張壓(DBP),血清白細胞介素-6(IL-6)、腫瘤壞死因子-α(TNF-α)、同型半胱氨酸(Hcy)和內(nèi)皮素-1(ET-1)水平及不良反應(yīng)情況。結(jié)果 治療后,治療組的總有效率(98.44%)明顯高于對照組(84.37%,P<0.05)。治療后,治療組嗜睡、頭暈、心悸、目眩緩解時間均明顯早于對照組(P<0.05)。治療后,兩組患者SBP、DBP水平明顯低于治療前(P<0.05),且治療組明顯低于對照組(P<0.05)。治療后,兩組血清IL-6、Hcy、TNF-α、ET-1水平明顯低于治療前(P<0.05),且治療組明顯低于對照組(P<0.05)。治療期間,治療組不良反應(yīng)發(fā)生率為7.81%,明顯低于對照組(14.06%,P<0.05)。結(jié)論 貝那普利與復(fù)方杜仲膠囊聯(lián)合治療老年高血壓能平穩(wěn)降低血壓,糾正血脂異常,降低炎性反應(yīng)。

Objective To investigate the efficacy of Compound Duzhong Capsules combined with benazepril in treatment of senile hypertension. Methods Patients (128 cases) with senile hypertension in the Third Hospital of Shijiazhuang from January 2020 to January 2022 were divided into control and treatment group according to random number method, and each group had 64 cases. Patients in the control group were po administered with Benazepril Hydrochloride Tablets, 10 mg/time, once daily. Patients in the treatment group po administered with Compound Duzhong Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, the relief time of symptom, SBP, DBP, the levels of IL-6, Hcy, TNF-α, and ET-1, and the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical therapeutic efficiency of the treatment group (98.44%) was significantly higher than that of the control group (84.37%, P＜0.05). After treatment, the remission time of drowsiness, dizziness, palpitation and dizziness in the treatment group was significantly earlier than that in the control group (P＜0.05). After treatment, the levels of SBP and DBP in two groups were significantly lower than those before treatment (P＜0.05), and those in the treatment group were significantly lower than those in the control group (P＜0.05). After treatment, the serum levels of IL-6, Hcy, TNF-α, and ET-1 in the two groups were significantly lower than those before treatment (P＜0.05), and which in the treatment group were significantly lower than those in the control group (P＜0.05). During the treatment, the adverse reaction rate in the treatment group was 7.81%, which was significantly lower than that in the control group (14.06%, P＜0.05). Conclusion Compound Duzhong Capsules combined with benazepril in treatment of senile hypertension can steadily reduce blood pressure, correct dyslipidemia and reduce inflammatory reaction.

R914

河北省醫(yī)學(xué)研究重點課題計劃項目(20201366)